Revolutionising cellular therapies for cancer and beyond

We’re developing more precise and more accessible treatment options for patients with solid cancers, endometriosis and Alzheimer’s disease

Pioneering excellence in the field of immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers, endometriosis and Alzheimer’s disease. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer and beyond.

Learn more about us

Some of our partners

Latest news

Using Gene-edited Killer Cells to Target Cancer, Endometriosis and Beyond

By Christine Filippis / June 12, 2025
Cartherics is delighted to be featured in the June 2025 issue of Pharma Technology Focus, drawing attention to our innovative...
Read More

Cartherics to present at the 2025 BIO International Convention

By Christine Filippis / May 28, 2025
Cartherics’ Chief Operating Officer, Dr. Ian Nisbet, will be presenting at BIO on Monday 16th June, 2025 at 1.30pm (US...
Read More

Bridging Borders: The Strategic Value of U.S.-Based Directors for Australian Biotech Companies

By Christine Filippis / May 19, 2025
Cartherics’ appointment of Laurence Nore underscores a growing trend with global implications.  As global demand for biotechnology products and services...
Read More